Filing Flows › GeneDx Holdings (WGS) › Q1 2025
GeneDx Holdings (WGS) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 30, 2025
GeneDx Holdings (WGS) reported revenue of $87.1M for the first quarter 2025 (Q1 2025), +40% from a year earlier and -9% from the quarter before. Operating margin was -5.2%, net loss $6.5M (7.5% of revenue).
GeneDx Holdings, Q1 2025: revenue $87.1M (+40% year over year), operating margin -5.2%, net loss $6.5M, operating cash flow $10.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $87.1M | -9% | +40% |
| Operating profit | −$4.6M | -152% | — |
| Net earnings | −$6.5M | -220% | — |
| Operating cash flow | $10.2M | — | — |
| Free cash flow | $4.1M | — | — |
What changed
Revenue was $87.1M in Q1 2025, up 40% year over year and down 9% from the previous quarter. Patients with third-party insurance was the largest line at 78% of revenue. Patients with third-party insurance added $24.2M year over year (up 55%), 98% of the total change. Self-pay patients declined 84%.
Gross margin was 67.1%, up 7.2 points from a year earlier. Operating costs exceeded revenue by $4.6M, an operating margin of -5.2%. Operating expenses grew 23% against revenue growth of 40%. The fastest-growing cost line was General & admin (+37%). The quarter ended with a net loss of $6.5M, after a profit of $5.4M the previous quarter.
Operating cash flow was $10.2M. Non-cash charges added back $5.7M of depreciation and amortization and $4.0M of share-based compensation. Working capital and other items added $7.0M. Capital expenditures of $6.1M left free cash flow of $4.1M.
Questions
What was GeneDx Holdings' revenue in the first quarter 2025?
GeneDx Holdings (WGS) reported revenue of $87.1M for the first quarter 2025 (Q1 2025), +40% from a year earlier and -9% from the quarter before.
Was GeneDx Holdings profitable in the first quarter 2025?
Operating loss was $4.6M (-5.2% of revenue) and net loss $6.5M.
Source: GeneDx Holdings 10-Q on SEC EDGAR.